Akari Therapeutics (AKTX) Short Interest Ratio & Short Volume → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Free AKTX Stock Alerts $1.47 -0.23 (-13.53%) (As of 05/2/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Akari Therapeutics Short Interest DataCurrent Short Volume600 sharesPrevious Short Volume10,500 sharesChange Vs. Previous Month-94.29%Dollar Volume Sold Short$720.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 15, 2024Outstanding Shares7,920,000 sharesFloat Size6,590,000 sharesShort Percent of Float0.01%Today's Trading Volume38,277 sharesAverage Trading Volume14,809 sharesToday's Volume Vs. Average258% Short Selling Akari Therapeutics ? Sign up to receive the latest short interest report for Akari Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAKTX Short Interest Over TimeAKTX Days to Cover Over TimeAKTX Percentage of Float Shorted Over Time Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. Akari Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024600 shares $720.00 -94.3%0.0%0.1 $1.20 3/31/202410,500 shares $19,582.50 +75.0%0.2%0.9 $1.87 3/15/20246,000 shares $11,820.00 -37.5%0.1%0.6 $1.97 2/29/20249,600 shares $21,216.00 +10.3%0.2%1.1 $2.21 2/15/20248,700 shares $20,706.00 +357.9%0.2%1 $2.38 1/31/20241,900 shares $4,807.00 -66.7%0.0%0.2 $2.53 Get the Latest News and Ratings for AKTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,700 shares $16,416.00 +375.0%0.1%0.5 $2.88 12/31/20231,200 shares $3,744.00 -29.4%0.0%0.1 $3.12 12/15/20231,700 shares $4,760.00 -50.0%0.0%0.1 $2.80 11/30/20233,400 shares $10,030.00 -69.6%0.1%0.3 $2.95 11/15/202311,200 shares $35,504.00 -36.0%0.2%0.7 $3.17 10/31/202317,500 shares $61,425.00 +49.6%0.4%0.8 $3.51 10/15/202311,700 shares $42,705.00 -33.5%0.2%0.4 $3.65 9/30/202317,600 shares $69,520.00 +2.9%0.4%0.7 $3.95 9/15/202317,100 shares $62,244.00 +116.5%0.5%0.6 $3.64 8/31/20237,900 shares $24,885.00 -24.8%0.2%0.3 $3.15 8/15/202310,500 shares $39,585.00 -95.7%0.3%0.3 $3.77 7/31/2023243,800 shares $60,852.48 -29.2%N/A0.5 $0.25 7/15/2023344,200 shares $58,961.46 +67.3%N/A0.6 $0.17 6/30/2023205,700 shares $34,948.43 -1.5%N/A0.4 $0.17 6/15/2023208,800 shares $32,760.72 -3.7%N/A0.4 $0.16 5/31/2023216,700 shares $38,334.23 -5.2%N/A0.4 $0.18 5/15/2023228,600 shares $42,153.84 +104.5%N/A0.5 $0.18 4/30/2023111,800 shares $20,246.98 -62.3%N/A0.3 $0.18 4/15/2023296,900 shares $59,409.69 +128.0%N/A0.8 $0.20 3/31/2023130,200 shares $23,657.34 -21.5%N/A0.5 $0.18 3/15/2023165,800 shares $42,776.40 +79.4%N/A1.3 $0.26 2/28/202392,400 shares $31,878.00 +42.2%N/A0.8 $0.35 2/15/202365,000 shares $29,250.00 -30.6%N/A0.7 $0.45 1/31/202393,700 shares $43,739.16 -15.9%N/A1.2 $0.47 1/15/2023111,400 shares $60,111.44 +47.2%N/A1.4 $0.54 12/30/202275,700 shares $35,571.43 -2.1%N/A0.9 $0.47 12/15/202277,300 shares $35,558.00 -43.0%N/A1 $0.46 11/30/2022135,500 shares $74,877.30 -8.2%N/A1.3 $0.55 11/15/2022147,600 shares $84,279.60 +313.5%N/A1.5 $0.57 10/31/202235,700 shares $16,629.06 -44.8%N/A0.4 $0.47 10/15/202264,700 shares $31,470.08 -16.8%N/A0.7 $0.49 9/30/202277,800 shares $49,014.00 +215.0%0.5%0.8 $0.63 9/15/202224,700 shares $16,796.00 -10.5%0.2%0.3 $0.68 8/31/202227,600 shares $32,844.00 -47.1%0.2%0.4 $1.19Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. AKTX Short Interest - Frequently Asked Questions What is Akari Therapeutics' current short interest? Short interest is the volume of Akari Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 600 shares of AKTX short. 0.01% of Akari Therapeutics' shares are currently sold short. Learn More on Akari Therapeutics' current short interest. What is a good short interest percentage for Akari Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.01% of Akari Therapeutics' floating shares are currently sold short. Is Akari Therapeutics' short interest increasing or decreasing? Akari Therapeutics saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 600 shares, a drop of 94.3% from the previous total of 10,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Akari Therapeutics' float size? Akari Therapeutics currently has issued a total of 7,920,000 shares. Some of Akari Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Akari Therapeutics currently has a public float of 6,590,000 shares. How does Akari Therapeutics' short interest compare to its competitors? 0.01% of Akari Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Akari Therapeutics: Elevai Labs, Inc. (0.32%), Imunon, Inc. (4.96%), MIRA Pharmaceuticals, Inc. (0.43%), RedHill Biopharma Ltd. (2.51%), Monopar Therapeutics Inc. (2.01%), Purple Biotech Ltd (0.93%), Moleculin Biotech, Inc. (1.24%), ABVC BioPharma, Inc. (6.14%), Kiora Pharmaceuticals, Inc. (0.31%), Molecular Templates, Inc. (6.97%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Akari Therapeutics stock? Short selling AKTX is an investing strategy that aims to generate trading profit from Akari Therapeutics as its price is falling. AKTX shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akari Therapeutics? A short squeeze for Akari Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKTX, which in turn drives the price of the stock up even further. How often is Akari Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ELAB Short Interest IMNN Short Interest MIRA Short Interest RDHL Short Interest MNPR Short Interest PPBT Short Interest MBRX Short Interest ABVC Short Interest KPRX Short Interest MTEM Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKTX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders